Injectable HIV Treatment to Begin Phase III Clinical Trials
Although advancements in treatment have made HIV much easier to manage, the daily dosage of medication can often feel like a burden. Researchers have been working hard to develop new ways treatment can be delivered to those living with HIV to improve adherence and increase viral suppression. Now, ViiV Healthcare and Janssen are one step closer to making life with HIV a lot easier.
Today, the two drug companies announced that Phase III trials will begin in mid-2016 for their bi-monthly two-drug long-term injectable treatment. The treatment formulation is a combination of cabotegravir (ViiV) and rilpivirine (Janssen) and is being investigated as an injectable maintenance treatment for people with HIV who have achieved viral suppression.
“As a company committed to innovation in the field of HIV, this agreement with Janssen will enable us to progress the development of the first long-acting, injectable two drug regimen,” said Dominique Limet, CEO, ViiV Healthcare. “If successful, this regimen would offer people living with HIV who have achieved viral suppression an alternative option to the standard oral daily, three drug therapy.”
In November, Phase IIb trials met its primary endpoint after just 32 weeks in the 96-week trial. Results showed the injectable formulation as being comparable to oral drug regimens in maintaining viral suppression.
If approved, ViiV and Janssen’s injectable treatment would allow for people with HIV to achieve higher viral suppression rates; improving the lives of people on treatment and driving down infection rates.